Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:MTSRNASDAQ:PRAXNASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$25.05+0.6%$23.57$14.75▼$26.16$3.06B0.71.11 million shs257,732 shsMTSRMetsera$28.61-2.5%$22.86$12.30▼$32.81$3.01BN/A871,889 shs311,899 shsPRAXPraxis Precision Medicines$41.34+0.3%$35.71$26.70▼$91.83$842.05M2.6384,695 shs137,471 shsVKTXViking Therapeutics$27.37+2.9%$25.76$18.92▼$81.73$3.07B0.754.07 million shs968,992 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.04%+0.28%+0.28%+13.80%+53.96%MTSRMetsera+4.37%+5.46%+14.42%+11.09%+2,934,999,900.00%PRAXPraxis Precision Medicines+3.47%+14.13%+2.39%+8.85%-12.43%VKTXViking Therapeutics+1.88%-2.10%-9.37%-4.76%-57.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.8856 of 5 stars3.63.00.03.94.03.32.5MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/APRAXPraxis Precision Medicines2.8225 of 5 stars4.42.00.00.02.71.70.0VKTXViking Therapeutics4.5533 of 5 stars4.52.00.04.72.53.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$32.2928.89% UpsideMTSRMetsera 3.00Buy$47.0064.28% UpsidePRAXPraxis Precision Medicines 2.80Moderate Buy$109.90165.84% UpsideVKTXViking Therapeutics 3.00Buy$87.15218.43% UpsideCurrent Analyst Ratings BreakdownLatest PRAX, VKTX, CPRX, and MTSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$97.005/7/2025PRAXPraxis Precision MedicinesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/5/2025PRAXPraxis Precision MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$26.00 ➝ $28.005/5/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/1/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$105.00 ➝ $105.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$534.65M5.71$2.34 per share10.72$3.30 per share7.59MTSRMetseraN/AN/AN/AN/AN/AN/APRAXPraxis Precision Medicines$8.12M103.68N/AN/A$7.92 per share5.22VKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$71.41M$1.5721.2311.763.3131.01%40.79%34.87%8/6/2025 (Estimated)MTSRMetseraN/AN/A0.00∞N/AN/AN/AN/AN/APRAXPraxis Precision Medicines-$123.28M-$10.72N/AN/AN/A-9,409.22%-54.86%-50.52%8/12/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)Latest PRAX, VKTX, CPRX, and MTSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/2/2025Q1 2025PRAXPraxis Precision Medicines-$3.20-$3.29-$0.09-$3.29$0.20 millionN/A4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/A3/26/2025N/AMTSRMetseraN/A-$3.52N/A-$3.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A5.114.92MTSRMetseraN/AN/AN/APRAXPraxis Precision MedicinesN/A10.9610.96VKTXViking TherapeuticsN/A36.4736.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%MTSRMetseraN/APRAXPraxis Precision Medicines67.84%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%MTSRMetseraN/APRAXPraxis Precision Medicines2.70%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.98 million106.15 millionOptionableMTSRMetsera81105.06 millionN/AN/APRAXPraxis Precision Medicines11020.37 million18.14 millionOptionableVKTXViking Therapeutics20112.31 million106.20 millionOptionablePRAX, VKTX, CPRX, and MTSR HeadlinesRecent News About These CompaniesProfit Investment Management LLC Buys 44,055 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)June 2 at 6:34 AM | marketbeat.comDeutsche Bank AG Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)June 2 at 3:42 AM | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires New Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 31, 2025 | marketbeat.comPKO Investment Management Joint Stock Co Purchases Shares of 15,000 Viking Therapeutics, Inc. (NASDAQ:VKTX)May 30, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Up 3.4% - Here's WhyMay 29, 2025 | marketbeat.comLighthouse Financial LLC Acquires Shares of 14,000 Viking Therapeutics, Inc. (NASDAQ:VKTX)May 29, 2025 | marketbeat.comViking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade)May 29, 2025 | seekingalpha.comNovo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?May 27, 2025 | zacks.comWoodline Partners LP Raises Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 27, 2025 | marketbeat.comWaverly Advisors LLC Increases Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 25, 2025 | marketbeat.comCastleark Management LLC Trims Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 24, 2025 | marketbeat.comBank of America Corp DE Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 24, 2025 | marketbeat.comViking Therapeutics: Weight-Loss Story Remains IntactMay 22, 2025 | seekingalpha.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Reduces Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 22, 2025 | marketbeat.comViking Therapeutics: A High Potential Biotech Play With Manageable RisksMay 20, 2025 | seekingalpha.comViking Therapeutics: Near-Term Catalysts And Competitor ReadoutsMay 20, 2025 | seekingalpha.comTang Capital Management LLC Grows Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 20, 2025 | marketbeat.comTema Etfs LLC Invests $813,000 in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 20, 2025 | marketbeat.comRaiffeisen Bank International AG Invests $477,000 in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 20, 2025 | marketbeat.comBNP Paribas Financial Markets Has $1.88 Million Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 20, 2025 | marketbeat.comSecond Line Capital LLC Purchases 11,393 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)May 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRAX, VKTX, CPRX, and MTSR Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$25.05 +0.14 (+0.56%) As of 01:14 PM EasternCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Metsera NASDAQ:MTSR$28.61 -0.74 (-2.52%) As of 01:15 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Praxis Precision Medicines NASDAQ:PRAX$41.34 +0.14 (+0.34%) As of 01:14 PM EasternPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Viking Therapeutics NASDAQ:VKTX$27.37 +0.76 (+2.86%) As of 01:16 PM EasternViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
